ElevenLabs Launches Eleven Music in Collaboration with Music Industry Partners
ElevenLabs, the leading AI audio research and product company, today announced the launch of Eleven Music, expanding on its mission to build the most comprehensive AI audio platform in the world. Eleven Music enables businesses, creators, artists, and everyday users to generate studio-grade music from natural language prompts. Eleven Music was built in partnership with artists, labels, and publishers, and includes guardrails to protect rightsholders.
Eleven Music users can effortlessly generate their ideal track, in any genre or style, with or without vocals, in numerous languages – and in a matter of minutes. Generated tracks can be used for nearly any application. ElevenLabs plans to integrate Eleven Music into its full suite of tools, including its Conversational AI platform.
“As an AI audio company, expanding into music was a natural progression, and we are thrilled to introduce Eleven Music today,” said Mati Staniszewski, CEO and Co-Founder of ElevenLabs. “We’ve heard massive demand from our enterprise partners and users for a music model like this and we took our time to ship one that we’re certain they’ll love. We’re proud to do so in collaboration with music industry partners who recognize the vast benefits and possibilities of AI innovation in music.”
ElevenLabs has worked with a range of partners to develop the first Eleven Music model. In addition, ElevenLabs has reached agreements with Merlin – the digital music licensing partner for the world’s leading independent labels and distributors – and Kobalt – the largest independent music publisher in the world. These groundbreaking deals will allow the premier artists and songwriters that Merlin and Kobalt represent to participate in the development of Eleven Music Pro, a subsequent model that the company plans to release in the coming months. The Merlin and Kobalt partnerships will help ElevenLabs continue to deliver the best AI audio tools to its millions of users.
“We are excited to partner with ElevenLabs,” said Jeremy Sirota, CEO of Merlin. “As we navigate the transformative yet challenging opportunities that AI presents, it is core to Merlin’s mission that we work with partners who respect the extraordinary cultural contribution of our members, their artists and their music. We will be very deliberate about who we work with and have been in conversations with many companies in this space. Our partnership with ElevenLabs demonstrates that music rightsholders can negotiate thoughtful, forward-looking agreements with AI companies. Together, we have created responsible guardrails that showcase how AI companies and music rightsholders can collaborate. We look forward to sharing further announcements as we work together towards the launch of Eleven Music Pro.”
Laurent Hubert, CEO of Kobalt said: “Our songwriters and clients entrust us to ensure that the AI revolution includes both strong protections for their intellectual property rights for AI training, as well as forward-looking and thoughtful opportunities to participate in AI revenue streams, subject to clear and fair guardrails. ElevenLabs has been a collaborative partner, committed to sourcing data directly from rightsholders and protecting them. We are excited about this partnership and seeing ElevenLabs become a pioneer in licensing premium music for their Music Pro offering. Kobalt looks forward to working with our songwriters and partners who wish to be part of this opportunity with ElevenLabs.”
Eleven Music is available today on the ElevenLabs website. Outputs are cleared for broad commercial use. For more information on supported usage, please visit elevenlabs.io/music-terms.
About ElevenLabs
Founded in 2022, ElevenLabs is the global leader in AI audio research and technology, building cutting-edge AI audio tools for enterprises, developers, creators, and artists. The platform empowers millions of individuals and thousands of businesses, including employees from over 72% of the Fortune 500, to quickly and affordably create high-quality voice overs at scale, launch interactive AI voice agents in over 30 languages, and now generate studio-quality music.
About Merlin
Merlin is the digital music licensing partner for the world’s leading independent labels and distributors. We’ve negotiated premium deals with Apple, Canva, Meta, Spotify, YouTube, and 40 other innovative platforms around the world. Our global membership is from 70+ countries around the world, representing 15% of the recorded music market. Merlin operates for the benefit of its members, without investors looking for an exit, and is funded entirely by our low 1.5% admin fee. Merlin helps the world’s leading independents to own their digital business through world-class deals and white-glove support.
Find out more at www.merlinnetwork.org.
About Kobalt
Kobalt Music is the leading independent music publishing destination for songwriters and publishers, powered by technology. Across 10 global offices, Kobalt serves over 1 Million songs, representing some of the biggest songwriters in the world. On average, Kobalt represents over 35% of the top 100 songs and albums in the US and the UK. With a relentless focus on advancing the interests of creators, Kobalt leverages cutting-edge technology to streamline the complex processes of music publishing administration. The company’s dedication to transparency, coupled with its forward-thinking approach, has positioned it as a trusted partner for songwriters and rights holders navigating the ever-evolving music industry.
Kobalt’s unwavering commitment to empowering creators and reshaping the future of music rights management solidifies its standing as a global leader in the music industry. The company continues to transform the industry, most recently via AMRA, its global digital music collection society designed to maximize value for songwriters and publishers in today's digital age, while providing the highest level of transparency and efficiency. For more information about Kobalt, please visit www.kobaltmusic.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250805333301/en/
Contacts
ElevenLabs Press Contact:
Sarah Bauer, press@elevenlabs.io
Merlin Press Contact:
Crystal Henderson, crystal@thepresshouse.com
Kobalt Press Contact:
John Vlautin, jv@spinlab.net
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press Release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press Release
Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press Release
Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which translate into thinner, more discreet and comfortable products. Its high compression capability enables s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom